Thomas Shrader
Stock Analyst at BTIG
(1.45)
# 3,391
Out of 4,905 analysts
49
Total ratings
34.15%
Success rate
-7.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Downgrades: Neutral | n/a | $104.90 | - | 4 | Jul 10, 2025 | |
| INMB INmune Bio | Downgrades: Neutral | n/a | $2.42 | - | 3 | Jul 1, 2025 | |
| ALDX Aldeyra Therapeutics | Maintains: Buy | $11 → $9 | $5.39 | +66.98% | 1 | Apr 7, 2025 | |
| OVID Ovid Therapeutics | Maintains: Buy | $5 → $4 | $0.55 | +627.27% | 3 | Mar 24, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $36.21 | +341.87% | 4 | Feb 24, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $41 | $13.50 | +203.70% | 1 | Jan 28, 2025 | |
| ALEC Alector | Maintains: Buy | $16 → $5 | $1.59 | +214.47% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.41 | - | 3 | Sep 4, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $2.07 | +286.47% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $0.44 | +1,717.77% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $4.61 | +1,201.52% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $14.05 | +70.82% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $2.32 | +201.72% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $5.81 | +158.18% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.35 | +3,593.18% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $1.59 | +530.91% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.50 | +1,366.67% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.43 | +3,466.43% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.30 | +595.65% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.24 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.00 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $10.49 | +452.91% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.24 | +141.94% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $124.99 | +176.82% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.19 | - | 1 | Jun 30, 2017 |
Verona Pharma
Jul 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $104.90
Upside: -
INmune Bio
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.42
Upside: -
Aldeyra Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $11 → $9
Current: $5.39
Upside: +66.98%
Ovid Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $0.55
Upside: +627.27%
Vaxcyte
Feb 24, 2025
Reiterates: Buy
Price Target: $160
Current: $36.21
Upside: +341.87%
Arcturus Therapeutics Holdings
Jan 28, 2025
Initiates: Buy
Price Target: $41
Current: $13.50
Upside: +203.70%
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $1.59
Upside: +214.47%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.41
Upside: -
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $2.07
Upside: +286.47%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.44
Upside: +1,717.77%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.61
Upside: +1,201.52%
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $14.05
Upside: +70.82%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $2.32
Upside: +201.72%
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $5.81
Upside: +158.18%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.35
Upside: +3,593.18%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $1.59
Upside: +530.91%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.50
Upside: +1,366.67%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.43
Upside: +3,466.43%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.30
Upside: +595.65%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.24
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $14.00
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $10.49
Upside: +452.91%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.24
Upside: +141.94%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $124.99
Upside: +176.82%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $1.19
Upside: -